Several viruses, such as Epstein-Barr virus, are now known to be associated with several human cancers, but not all patients with these viral infections develop cancer. In transplantation, such viruses often have a prolonged time gap from infection to cancer development, and many are preceded by a period of circulating and detectable nucleic acids in the peripheral blood compartment. The interpretation of a viral load as a measure of posttransplant risk of developing cancer depends on the virus, the cancer and associated pathogenic factors. This review describes the current state of knowledge regarding the utility and limitations of peripheral blood nucleic acid testing for Epstein-Barr virus in surveillance and risk prediction for posttransplant lymphoproliferative disorders.
Introduction
Viral infections, including some hepatitis and herpes group viruses, have been implicated in 15% of all human cancers (1) . Oncogenic viruses have putative or known oncogenes that can subvert the growth cycle controls of the cells by turning off tumor suppressor genes or other mechanisms or that may initiate a cascade of accumulating genetic mutations by co-opting signaling pathways or integrating into the host genome. Nevertheless, only a proportion of persons infected by these oncogenic viruses will develop specific cancers (2) . Unlike hepatitis B and C infections, antiviral therapy has not been as successful in treating infections and consequent malignancies from other viruses such as herpesviruses (3) . Effective vaccines can prevent cervical cancer associated with human papillomavirus, but no effective vaccine exists for Epstein-Barr virus (EBV). For viruses with a higher incidence of cancer in immunosuppressed populations, early and accurate prediction of cancer risk is desirable and represents an unmet need.
Some of the viral nucleic acids from infected host cells can reach and circulate in the host's peripheral blood prior to cancer development. Polymerase chain reaction (PCR) technology has enabled the detection of human and microbial nucleic acids from samples such as peripheral human blood (4) . This technology has also brought forth the possibility of early detection of oncogenic viruses in peripheral blood, either prior to or at an early stage of cancer development.
EBV and Cancers
EBV is associated with several different cancers, such as Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma (NPC), immune-suppressed B cell lymphoma, posttransplant lymphoproliferative disorders (PTLDs; 75% are associated with EBV), and gastric carcinoma (10% are associated with EBV) (3). In-depth reviews of PTLDs are beyond the scope of this minireview but are available elsewhere (5-7).
EBV initially infects humans through the oropharyngeal route, usually in early childhood in developing countries but possibly later in developed countries. The virus targets the human reticuloendothelial cells, such as B cells, which it penetrates by interactions of its glycoprotein 350 receptor with the B cell CD21 cell surface receptor ( Figure 1 ). The virions then insert themselves into the host nucleus, either as circular episomal viral DNA (8) or by integration of the viral genome into the host genome (9) , allowing for transcription of viral proteins and new episomes that can lyse the host cells and allow the now-encapsulated virions to circulate. As the host's immune response identifies and reacts to the foreign invader, the virus shifts from lytic cycle gene expression to latency gene expression, allowing long-lived latent survival within quiescent host memory B cells. In the initial latency III pattern, nine EBV gene products are expressed but are highly immunogenic; to avoid immune recognition, EBV shifts down to the latency II pattern (five genes) and then to the latency 0 pattern, characterized by expression of only Epstein-Barr-encoded RNA. EBV-specific CD8-lineage T effector cells, typically of the memory phenotype, prevent the uncontrolled proliferation of these latent virus-infected B cells. In immunocompetent people, an immunological truce is achieved.
EBV DNA can be detected at high levels in peripheral blood during the initial infection, followed by a drop in latency phase, with occasional low-level positivity (10) . The levels may rise again prior to onset of neoplasia. Notably, in immunocompetent people, EBV is associated with only a small percentage of Hodgkin lymphomas. In humans with widespread and nonspecific suppression of the immune system, either intrinsic (e.g. human immunodeficiency virus [HIV] infection and AIDS) or extrinsic (e.g. transplant immunosuppression), the latent EBV within B cells can permit B cells to escape CD8 T cell control and proliferate unchecked (11).
The detailed mechanisms by which EBV leads to malignant transformation of host immune cells is still under active investigation. Multiple pathways appear to be involved, as reviewed elsewhere (7) . Among the different EBV genes, latent membrane proteins (LMPs; LMP1 and LMP2) and Epstein-Barr nuclear antigens (EBNAs) have received the most attention (12) . In particular, LMP1 is known to inhibit apoptosis and to drive proliferation of host B cells. EBNA2 and EBNA3 also drive B cell transformation. In addition, EBV-positive PTLDs express the ligand PDL1, which promotes exhaustion of activated T cells. Finally, EBV expresses its own microRNAs (miRNAs), which override the host miRNA machinery to stimulate cytokine IL-10 production to inhibit viral-specific T effector cells (13) . At a later stage, the EBV oncogenes induce cytogenetic alterations in the B cell genome, leading to development of lymphomas of either the Hodgkin or non-Hodgkin type.
The time gap between viral nucleic acid detection in peripheral blood to full malignant transformation of memory B cells offers an opportunity for early cancer detection and prevention. Studies have also suggested that the higher the viral load log value, the greater the risk of PTLDs (14) or of NPC or NK/T cell lymphoma (15) . In transplant recipients, <10% of patients with EBV viral loads of 3-4 log copies per milliliter of whole blood (copies/mL) developed PTLDs, whereas of those who had levels >6 log copies/mL, 50% developed PTLDs (14) . Similarly, the lower stages of NPC were associated with median EBV loads of a few hundred copies/mL versus a few thousand copies/mL at higher or metastatic stages (15) . Nevertheless, an elevated EBV load per se does not distinguish among risk of EBV disease, presence of EBV disease, and risk or presence of EBVassociated malignancy. In addition, the load does not distinguish between different stages of PTLDs and cannot predict the exact point of transformation between stages, in part because such cutoff points between PTLD stages are not known.
Source of EBV DNA
The three main sources of EBV DNA measurement are whole blood, peripheral blood mononuclear cells (PBMCs) or plasma. In Hodgkin lymphoma or NPC in the general population, episomal or naked EBV (cell-free) DNA, derived from apoptotic cells, passes into the peripheral blood. Some latently EBV-infected tumor cells may also leak into the bloodstream. EBV load in the serum or plasma (not PBMCs) correlates with response and prognosis (16) . Routine viral surveillance of peripheral blood is not routinely practiced in healthy populations to detect these cancers.
In transplant recipients, EBV DNA can originate from within cells or liquid fractions of blood. Unlike immunocompetent patients, whole blood frequently tends to be positive in transplant recipients, seen in one study in 40% of 6198 samples over the first year after transplant (17) . Whole blood and PBMCs show a moderately strong Spearman correlation. Whole blood and PBMCs also tend to run much higher EBV loads than seen in plasma, which does not correlate well with either whole blood or PBMCs. Consequently, the sensitivity of whole blood and PBMCs for EBV DNA detection is higher, but transplant clinicians often see low positive results of uncertain significance with whole blood testing.
Controversy remains about which compartment is superior for PTLD risk assignment. Wagner et al found that plasma had superior sensitivity (100%) and specificity (also 100%) at a cutoff of 1000 copies/mL (18). Wada et al, however, found that median EBV plasma levels were nearly identical between asymptomatic and symptomatic transplant recipients, whereas median whole blood levels were significantly higher in the symptomatic group (19) . Ruf et al (20) found that adding the plasma load to the whole blood load improved the test performance, but positive predictive value remained very low at 50%. At this time, guidelines state that no recommendations can be made about the type of sample preferred (21) . Most centers have to work with whatever type of sample their laboratory has contracted to use.
Other Variations in the EBV PCR Assay
Besides the source of the sample, many other aspects of the EBV PCR assay from peripheral blood are not standardized. EBNA1, expressed by EBV at all stages and in all diseases, is the target gene in all commercial assays, but the amplicons are different and of various lengths between commercial assays, ranging from 68 to 155 base pairs. Most laboratories at major centers have developed their own assays for EBV nucleic acid testing. Preiksaitis et al sent 28 laboratories a fixed blinded sample of EBV (22) . The variability in EBV PCR results was high, ranging 2-3 log fold in either direction from the expected result using either laboratory-developed or commercial assays. These results led to the development of a World Health Organization international standard for EBV nucleic acid testing: a whole virus preparation of the EBV B95-8 strain type 1 assigned a concentration of 5 9 10 6 international units when reconstituted in 1 mL of nuclease-free water (http://www. nibsc.org/documents/ifu/09-260.pdf).
Using the EBV standard, variability in results between laboratories was reduced, but 1-2 log-fold differences between expected and observed results persisted using a variety of assays (23) . These results suggest that other components of the assay, such as extraction method, amplification reagents and calibrators used, might account for the persistent variability.
In an extensive review, Gartner and Preiksaitis (24) found that both the cutoff values and the units differ depending on the study, with copies/mL being most common, followed by copies/10 6 PBMCs and, rarely, copies/lg DNA. The cutoff also seems to vary based on the population being studied and the assay used to measure the load; therefore, no specific cutoff can be recommended. Figure 2 shows a suggested algorithm of interventions based on stable or rising viral load.
EBV Loads in HIV-Induced Immunosuppression
Interestingly, one study (25) found that EBV loads trended higher in Kaposi sarcoma cases in HIV patients (p = 0.07). EBV loads were higher when EBV-associated lymphomas developed in HIV-infected patients, but the PBMC levels fluctuated over time, and longitudinal studies showed poor prediction (26) .
Different Patterns of EBV Load in Transplant Recipients
Multiple patterns of Epstein-Barr viremia can be seen in transplant recipients. Not surprisingly, an EBV seromismatch (donor positive to recipient negative) that leads to primary infection represents the single highest risk factor for PTLD development (27) . Patients with a primary infection can present with a high viral load a few weeks to months after transplant. Some transplant recipients may still be able to mount an EBV-directed CD8 T cell response. These patients will have a rapid drop of their viral load with no further increases (believed to be low at risk for PTLDs). Patients who cannot mount a response will display a rising load (believed to be at high risk). Some patients, however, may show variable degrees of immune control at different time points. Some transplant recipients may experience reactivation of the EBV already present within their bodies prior to transplant. These patients can show either (a) an intermittent but recurring spike pattern of moderately high loads with either very low or negative loads in between or (b) a chronic high load state in which loads are above a certain threshold at multiple time points over a period of time.
The load threshold varies with the study. Both patterns seem to be associated with intermediate risk, but the risk varies by organ transplanted and possibly by the degree of immunosuppression.
A chronic high load state after heart transplant (>16 000 genome copies/mL in ≥50% of samples over ≥6 mo) is associated with a very high 45% progression rate to PTLDs (28), whereas only 3-11% of liver and intestinal transplant recipients with the same criteria progressed to PTLDs (29, 30) . Sustained viral load >500 copies/10 5 PBMCs for >6 mo was associated with PTLD progression in 25% of liver transplant recipients in another study (31) . In kidney transplant recipients in studies using different definitions of chronic high load, PTLD rates were lower: 8% with any positive result ≥6 mo apart (32) or 0% with >1000 copies/lg DNA for >6 mo (33). We do not know currently whether the different rates in different organs, regardless of load pattern, are related to differing intensity of immunosuppression, different loads of EBV within the organ tissue or different risks of exposure to community EBV. Further studies of the natural history of rising and high loads, without intervention, are probably most appropriate in those patients who are not at high risk of PTLDs.
Pattern Analysis
To enhance the predictive ability of EBV load patterns, Cho et al performed a retrospective analysis of EBV DNA quantitation data from 9779 whole blood samples from 740 transplant patients, collected between 2003 and 2013 (34) . The area under the receiver operating characteristic curve (AUC) for peak EBV level was 0.752, with sensitivity of 58% and specificity of 88% at a cutoff of 105 000 copies/mL. The AUC for a rate of increase of EBV level by 29 280 copies/mL per week was 0.730, with sensitivity of 60% and specificity of 86%. In multivariate analysis, only the peak level was associated with PTLD (odds ratio 6.6, 95% confidence interval 3.11-14) .
Guidelines for EBV Monitoring in Transplant Recipients
At this time, there are several recommendations for how frequently to monitor the EBV PCR in the posttransplant period, whereas many centers follow their own individual protocols (35) . frequent monitoring over a whole year (21) . This newer guideline cites insufficient data to support routine monitoring beyond the first year. Another guideline published in 2009 by the Kidney Disease Improving Global Outcomes group suggests monitoring in the donor-positive/ recipient-negative seromismatch situation only or following treatment for acute rejection (37) . One study showed that a missed gap of >3 mo in EBV PCR testing significantly raised the risk of PTLDs (38) .
Pairing the Viral Load With an Immune Response Assay
Somewhat higher accuracy of prediction can be shown if the EBV PCR load is paired with an immune function assay, some of which are reviewed by Gulley and Tang (39) and can include (a) EBV-cytotoxic lymphocyte responses, either by interferon c enzyme-linked immunospot or tetramer assay (40); (b) lymphocyte surface markers (41, 42) ; (c) chemokine CXL13 assays (43); or (d) CD4 intracellular adenosine triphosphate production. Each of these assays needs validation in larger multicenter studies in independent populations. These additional tests are also expensive and labor intensive, and thus their use has not become widespread.
In the nontransplant setting, epigenetic alterations occur in EBV and then are induced in the host cell genomes in gastric carcinoma and NPC (44) . EBV, like other viruses, also encodes several miRNAs that contribute to malignancy pathogenesis (45) . Further study of these pathways may improve the currently unsatisfactory situation for monitoring.
Conclusions
Peripheral blood detection of viral DNA and serial detection of increasing viral copy number under immunomodulation is an attractive hypothesis for early cancer detection. The variability in results between different laboratories for EBV means that using one laboratory with one standardized EBV reverse transcriptase PCR assay is preferable for monitoring trends. In the author's opinion, a fully standardized EBV PCR assay that has the same primers, reagents and process throughout might allow for more definitive development of thresholds for prediction when multiple laboratories must be used. Further large-scale studies should then be performed in a prospective, multicenter, multiorgan format to improve monitoring and intervention strategies.
